Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Ginkgo biloba extract 50 dropping pills, Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant.
- Who it may be relevant to
- Registry conditions: Mild Cognitive Impairment. Basic parameters: 50 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Study on Ginkgo Biolba Extract Fifty in the Treatment of Mild Cognitive Impairment Associated With Cerebral Small Vessel Disease
Overview
This study aimed to explore the efficacy and safety of Ginkgo Biolba Extract fifty in treating mild cognitive impairment associated with cerebral small vessel disease (CSVD). Subjects included based on eligibility criteria were randomized into treatment and control groups. Patients will receive the drug or placebo for 12 months. Patients were followed at baseline and at 3 months, 6 months, and 12 months after randomization. The primary outcome was the difference from baseline in the Montreal Cognitive Assessmen (MoCA) score at 12 months after randomization.
Interventions
- Drug Ginkgo biloba extract 50 dropping pills
Composition: Ginkgo ketone ester, excipient polyethylene glycol 6000. Size: 10mg ginkgolides/pill. - Drug Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant
Composition: The main ingredient is polyethylene glycol 6000 + caramel pigment, placebo and ginkgolide drops are basically the same in color, odor and appearance. Size: 10 mg analog ingredient/pill.
Primary outcome measures
- Change from baseline in Montreal Cognitive Assessment Scale [Time frame: At 12months±14days after randomization.]
Secondary outcome measures (6)
- Change from baseline in Montreal Cognitive Assessment Scale [Time frame: At 3months±7days and 6months±14days after randomization.]
- Changes from baseline in total cerebral small vessel disease burden [Time frame: At 12months±14days after randomization.]
- Changes from baseline in Mini-mental State Examination score [Time frame: At 3months±7days, 6months±14days and 12months±14days after randomization.]
- Change from baseline in the Ability Daily Living score [Time frame: At 3months±7days, 6months±14days and 12months±14days after randomization.]
- Change from baseline in Social functioning questionnaire [Time frame: At 3months±7days, 6months±14days and 12months±14days after randomization.]
- Change from baseline in biomarkers [Time frame: At 3months±7days, 6months±14days and 12months±14days after randomization.]
Eligibility criteria
Inclusion criteria
- Age 50-75 years old, with no limitation on sex.
- Head MRI showed SVD lesions. High white matter signal, Fazekas score ≥2 and meet one of the following requirements:
Have ≥2 vascular risk factors (hypertension, hyperlipidemia, diabetes, current smoking); Combined lacunar foci; Combined with a new subcortical lacunar infarction (within 7 days of onset);
- Mild vascular cognitive impairment (memory and/or other cognitive domain abnormalities lasting for at least 3 months) with a score of 18 ≤MoCA score < 26.
- Insufficient cognitive impairment to affect independence of life (mRS≤2).
- After enrollment, you can live in the local stable for more than two years.
- Sign the informed consent form.
Exclusion criteria
- Known or suspected allergy to the components of the investigational drug or allergic constitution.
- With other brain diseases: Alzheimer's disease, Lewy body dementia, Parkinson's disease frontotemporal dementia, Crohn's disease, as well as other diseases that can lead to cognitive impairment, such as subdural hematoma, communicating hydrocephalus, brain tumors, drug poisoning, alcoholism, thyroid disease, and vitamin deficiency.
- Previous diagnosis of genetic/degenerative/inflammatory related small cerebral vascular diseases, such as CADASIL, CARASIL, etc.
- Concomitant with major depressive disorder (≥24 score in HAMD-17) or other transient organic psychosis (e.g., schizophrenia) that meets DSM-V criteria.
- Any medication used to treat cognitive impairment in the 4 weeks prior to randomization.
- Combined with severe neurological impairment, such as convenient hand hemiplegia, aphasia, auditory and visual impairment, the relevant examination or scale evaluation can not be completed.
- Combined with severe gastrointestinal diseases such as indigestion, gastrointestinal obstruction, gastric and duodenal ulcers that can affect drug absorption, or inability to swallow medication.
- Liver enzymes (ALT, AST)>2 times the upper limit of normal value, creatinine>1.2 times the upper limit of normal value, and decreased glomerular filtration rate (<90ml/min).
- Life expectancy < 1 year, or other reasons for not being able to complete follow-up.
- Pregnant or lactating women, or those with fertility plans.
- Has participated in other clinical trials.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06495476 · KY2024-090-01